COST-ANALYSIS OF THE INTRODUCTION OF PBPC FOR AUTOLOGOUS TRANSPLANTATION - EFFECT OF SWITCHING FROM BONE-MARROW (BM) TO PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC)

Increasingly, PBPC instead of BM are used for autologous transplantati on. Limited data exist on the economic effects of this change, Using a resource-based utilization model we prospectively determined the cost s of 48 autologous transplants (eight BM, 17 BM + PBPC, 23 PBPC), isol ating the post-reinfusion period (day 0 to discharge) to better determ ine the effect of the rescue product, Length of stay post-reinfusion w as significantly shorter in patients receiving PBPC (median 13 days) o r BM + PBPC (median 14 days) vs BM alone (median 20 days) (P < 0.01), Accordingly, transplant admission costs were less in the PBPC groups ( PBPC $22089, BM + PBPC $23 179) vs the BM alone group ($32 289) (P < 0 .05), Rescue product acquisition costs were higher for PBPC (range $34 39-$5157) vs BN ($2766) but these costs were offset by the more rapid recovery of patients receiving PBPC, Overall transplant costs depend o n the conditioning regimen with a 10-fold cost variation among regimen s, Modeled costs for autologus transplantation using various approache s to rescue product acquisition are given, The introduction of PBPC fo r autologus transplantation has resulted in cost savings at our instit ution, Although the acquisition costs of PBPC rescue product are great er than for BM, this incremental expense is more than offset by a less expensive post-reinfusion period.